Thalidomide BMS (previously Thalidomide Celgene) (thalidomide)
- Region
- 🇪🇺 EU
- Active substance
- thalidomide
- Company
- Bristol-Myers Squibb Pharma EEIG
- Status
- Authorised
- Therapeutic area
- Multiple Myeloma
- EU approval
- Wed 16 Apr 2008
- Application
- EMEA/H/C/000823
- ATC
- L04AX02
- Official record
- www.ema.europa.eu
Indication
Thalidomide BMS in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. Thalidomide BMS is prescribed and dispensed according to the Thalidomide Celgene Pregnancy Prevention Programme (see section 4.4).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Thalidomide Lipomed Authorised · Lipomed GmbH
Follow Thalidomide BMS (previously Thalidomide Celgene)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.